BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Gastric cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
90 results:

  • 1. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Mucin phenotype and genetic alterations in non-V600E braf-mutated colorectal cancer.
    Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
    Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
    Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
    Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
    Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
    Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].
    Wu LL; Cai MZ; Wang BG; Deng JY; Ke B; Zhang RP; Liang H; Wang XN
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):680-688. PubMed ID: 37583026
    [No Abstract]    [Full Text] [Related]  

  • 6. Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities.
    Song J; Wang SY; Wang X; Jia MQ; Tian XY; Fu XJ; Jin CY; Zhang SY
    Bioorg Chem; 2023 Aug; 137():106580. PubMed ID: 37149948
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
    Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
    Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Landscape of KRAS, braf, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable gastric cancer].
    Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
    Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma.
    Evaristo G; Katz A; Ramírez-GarcíaLuna JL; Issac MSM; Sangwan V; Thai DV; Bertos N; Guiot MC; Camilleri-Broët S; Marcus V; Mueller C; Cools-Lartigue J; Fiset PO; Ferri LE
    Can J Surg; 2023; 66(1):E79-E87. PubMed ID: 36792128
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Unsuspected gastric glomus tumour.
    Stahl C; Wong WG; Fanburg-Smith JC; Vining CC
    BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707101
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal cancers.
    Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
    Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
    Xu T; Wang X; Xin Y; Wang Z; Gong J; Zhang X; Li Y; Ji C; Sun Y; Zhao F; Huang D; Bai Y; Li J; Shen L
    Cancer Res Treat; 2023 Apr; 55(2):626-635. PubMed ID: 36550683
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A prospective cohort study of TIMP1 as prognostic biomarker in gastric and colon cancer.
    Macedo FC; Cunha N; Pereira TC; Soares RF; Monteiro AR; Bonito N; Valido F; Sousa G
    Chin Clin Oncol; 2022 Dec; 11(6):43. PubMed ID: 36509552
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
    Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
    [No Abstract]    [Full Text] [Related]  

  • 15. Primary colonic melanoma: a rare entity.
    Xie J; Dai G; Wu Y
    World J Surg Oncol; 2022 Aug; 20(1):256. PubMed ID: 35948931
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
    Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
    JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Applicability of endoscopic submucosal dissection for patients with early gastric cancer beyond the expanded indication for endoscopic submucosal dissection.
    Song JH; Lee S; Park SH; Kottikias A; Abdulmohsen A; Alrashidi N; Cho M; Kim YM; Kim HI; Hyung WJ
    Surg Endosc; 2022 Nov; 36(11):8349-8357. PubMed ID: 35546209
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.
    Shimozaki K; Shinozaki E; Yamamoto N; Imamura Y; Osumi H; Nakayama I; Wakatsuki T; Ooki A; Takahari D; Ogura M; Chin K; Watanabe M; Yamaguchi K
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1273-1283. PubMed ID: 35438321
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. gastric Carcinoma with Lymphoid Stroma: A Combination of Mismatch Repair Deficient Medullary Type and Epstein-Barr Virus-associated gastric Carcinomas.
    Uner M; Isık A; Oztop S; Karabulut E; Demirkol-Canlı S; Akyol A
    Int J Surg Pathol; 2022 Sep; 30(6):623-633. PubMed ID: 35188817
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
    Jeffers M; Kappeler C; Kuss I; Beckmann G; Mehnert DH; Fredebohm J; Teufel M
    Gastric Cancer; 2022 May; 25(3):598-608. PubMed ID: 35050442
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.